220 related articles for article (PubMed ID: 10832433)
21. Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
Wilson MK; Karakasis K; Oza AM
Lancet Oncol; 2015 Jan; 16(1):e32-42. PubMed ID: 25638553
[TBL] [Abstract][Full Text] [Related]
22. Endpoints in cancer clinical trials.
Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
[TBL] [Abstract][Full Text] [Related]
23. Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers.
Follen M; Meyskens FL; Alvarez RD; Walker JL; Bell MC; Storthz KA; Sastry J; Roy K; Richards-Kortum R; Cornelison TL
Cancer; 2003 Nov; 98(9 Suppl):2044-51. PubMed ID: 14603541
[TBL] [Abstract][Full Text] [Related]
24. Individual- and trial-level surrogacy in colorectal cancer.
Buyse M; Burzykowski T; Michiels S; Carroll K
Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
[TBL] [Abstract][Full Text] [Related]
25. [Significance of prolonged NC as an endpoint of chemotherapy for solid tumors].
Takahashi Y; Mai M
Gan To Kagaku Ryoho; 2000 May; 27(5):683-8. PubMed ID: 10832435
[TBL] [Abstract][Full Text] [Related]
26. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
27. Surrogate endpoints in clinical trials: cancer.
Ellenberg S; Hamilton JM
Stat Med; 1989 Apr; 8(4):405-13. PubMed ID: 2727464
[TBL] [Abstract][Full Text] [Related]
28. Surrogate endpoints and newer risk markers in atherosclerosis management.
Ballantyne CM
Am J Manag Care; 2001 May; 7(5 Suppl):S144-7. PubMed ID: 11383376
[TBL] [Abstract][Full Text] [Related]
29. Statistical evaluation of biomarkers as surrogate endpoints: a literature review.
Weir CJ; Walley RJ
Stat Med; 2006 Jan; 25(2):183-203. PubMed ID: 16252272
[TBL] [Abstract][Full Text] [Related]
30. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients.
Bruzzi P; Del Mastro L; Sormani MP; Bastholt L; Danova M; Focan C; Fountzilas G; Paul J; Rosso R; Venturini M
J Clin Oncol; 2005 Aug; 23(22):5117-25. PubMed ID: 15955906
[TBL] [Abstract][Full Text] [Related]
31. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
Powers JH
Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
[TBL] [Abstract][Full Text] [Related]
32. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?
Gill S; Sargent D
Oncologist; 2006 Jun; 11(6):624-9. PubMed ID: 16794241
[TBL] [Abstract][Full Text] [Related]
33. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development.
Colburn WA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1419-27. PubMed ID: 11185662
[TBL] [Abstract][Full Text] [Related]
34. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language.
Glynne-Jones R; Mawdsley S; Novell JR
Colorectal Dis; 2006 Nov; 8(9):800-7. PubMed ID: 17032329
[TBL] [Abstract][Full Text] [Related]
35. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
[TBL] [Abstract][Full Text] [Related]
36. A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials.
Molenberghs G; Burzykowski T; Alonso A; Assam P; Tilahun A; Buyse M
Stat Methods Med Res; 2010 Jun; 19(3):205-36. PubMed ID: 19608602
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers as surrogate endpoints in cancer trials.
Dunn BK; Akpa E
Semin Oncol Nurs; 2012 May; 28(2):99-108. PubMed ID: 22542317
[TBL] [Abstract][Full Text] [Related]
38. A new and rapid scoring system to assess the scientific evidence from clinical trials.
Silber S
J Interv Cardiol; 2006 Dec; 19(6):485-92. PubMed ID: 17107362
[TBL] [Abstract][Full Text] [Related]
39. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints.
Lassere MN
Stat Methods Med Res; 2008 Jun; 17(3):303-40. PubMed ID: 17925313
[TBL] [Abstract][Full Text] [Related]
40. Selection of response criteria for clinical trials of sarcoma treatment.
Schuetze SM; Baker LH; Benjamin RS; Canetta R
Oncologist; 2008; 13 Suppl 2():32-40. PubMed ID: 18434637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
